Androgen-independent growth and tumorigenesis of prostate cancer cells are enhanced by the presence of PKA-differentiated neuroendocrine cells

Cancer Research

Volumn 67, Issue 8, 2007, Pages 3663-3672

  Deeble, Paul D ^a,c   Cox, Michael E ^d   Frierson Jr , Henry F ^b   Sikes, Robert A ^e   Palmer, Jodie B ^d   Davidson, Robert J ^a   Casarez, Eli V ^a   Amorino, George P ^a   Parsons, Sarah J ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c MARY BALDWIN COLLEGE   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e UNIVERSITY OF DELAWARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; PROSTATE SPECIFIC ANTIGEN; TETRACYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CARCINOGENESIS; CASTRATION; CELL ANCHORAGE; CELL DIFFERENTIATION; CELL GROWTH; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MITOSIS RATE; NEUROSECRETORY CELL; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; CATALYTIC DOMAIN; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOSIS; NEOPLASMS, HORMONE-DEPENDENT; NEUROENDOCRINE TUMORS; PEPTIDES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 34248512597     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2616     Document Type: Article

References (43)

1. Krijnen JL, Bogdanowicz JF, Seldenrijk CA, Mulder PG, van der Kwast TH. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997;158:171-4.
2. di Sant'Agnese PA. Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 1992;23: 287-96.
3. Guate JL, Escaf S, Menendez CL, del Valle M, Vega JA. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment. Urol Int 1997;59:149-53.
4. Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991;19:91-8.
5. Abrahamsson PA. Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate Suppl 1996;6:3-8.
6. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. [reviews] [52 refs]. Prostate 1996;28:98-106.
7. di Sant' Agnese PA. Neuroendocrine differentiation in the precursors of prostate cancer. Eur Urol 1996;30: 185-90.
8. Pruneri G, Galli S, Rossi RS, et al. Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy. Prostate 1998;34:113-20.
9. Amorino GP, Parsons SJ. Neuroendocrine cells in prostate cancer. Crit Rev Eukaryot Gene Expr 2004;14: 287-300.
10. Dauge MC, Delmas V. A.P.U.D. type endocrine tumour of the prostate. Incidence and prognosis in association with adenocarcinoma. Prog Clin Biol Res 1987;243A:529-31.
11. Cohen RJ, Glezerson G, Haffejee Z. Neuro-endocrine cells; a new prognostic parameter in prostate cancer. Br J Urol 1991;68:258-62.
12. Tarle M, Frkovic-Grazio S, Kraljic I, Kovacic K. A more objective staging of advanced prostate cancer: routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values. Prostate 1994;24:143-8.
13. Weinstein MH, Partin AW, Veltri RW, Epstein JI. Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996;27:683-7.
14. Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF. Cathepsin D and chromogranin a as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 1997;80:2109-19.
15. Bostwick DG, Qian J, Pacelli A, et al. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival. J Urol 2002;168:1204-11.
16. Hvamstad T, Jordal A, Hekmat N, Paus E, Fossa SD. Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol 2003;44:215-21.
17. Bonkhoff H. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate Suppl 1998;8:18-22.
18. Bang YJ, Pirnia F, Fang WG, et al. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci U S A 1994;91:5330-4.
19. Cox ME, Deeble PD, Lakhani S, Parsons SJ. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. Cancer Res 1999;59:3821-30.
20. Shen R, Dorai T, Szaboles M, Katz AE, Olsson CA, Buttyan R. Transdifferentiation of cultured human prostate cells to a neuroendocrine cell phenotype in a hormone-depleted medium. Urol Res 1997;3:67-75.
21. Farini D, Puglianiello A, Mammi C, Siracusa G, Moretti C. Dual effect of pituitary adenylate cyclase activating polypeptide on prostate tumor LNCaP cells: short- and long-term exposure affect proliferation and neuroendocrine differentiation. Endocrinology 2003;144: 1631-43.
22. Qiu Y, Robinson D, Pretlow TG, Kung HJ. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci U S A 1998;95:3644-9.
23. Wang Q, Horiatis D, Pinski J. Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation. Int J Cancer 2004;111:508-13.
24. Cox ME, Deeble PD, Bissonette EA, Parsons SJ. Activated 3′,5′-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line. J Biol Chem 2000; 275:13812-8.
25. Rosenstein JM. Developmental expression of neuron-specific enolase immunoreactivity and cytochrome oxidase activity in neocortical transplants. Exp Neurol 1993;124:208-18.
26. Ismail AH, Landry F, Aprikian AG, Chevalier S. Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate. Prostate 2002; 51:117-25.
27. Burchardt T, Burchardt M, Chen MW, et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999; 162:1800-5.
28. Evangelou AI, Winter SF, Huss WJ, Bok RA, Greenberg NM. Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype. J Cell Biochem 2004;91:671-83.
29. Deeble PD, Murphy DJ, Parsons SJ, Cox ME. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells. Mol Cell Biol 2001;21:8471-82.
30. Dizeyi N, Bjartell A, Nilsson E, et al. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate 2004;59: 328-36.
31. Thalmann GN, Anezinis PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-81.
32. Chang JH, Gill S, Settleman J, Parsons SJ. c-Src regulates the simultaneous rearrangement of actin cytoskeleton, p190RhoGAP, and p120RasGAP following EGF stimulation. J Cell Biol 1995;130:1-14.
33. Ely CM, Oddie KM, Litz JS, et al. A 42-kD tyrosine kinase substrate linked to chromaffin cell secretion exhibits an associated MAP kinase activity and is highly related to a 42-kD mitogen-stimulated protein in fibroblasts. J Cell Biol 1990;110:731-42.
34. Reuter CW, Catling AD, Weber MJ. Immune complex kinase assays for mitogen-activated protein kinase and MEK. Methods Enzymol 1995;255:245-56.
35. Maa MC, Leu TH, McCarley DJ, Schatzman RC, Parsons SJ. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers. Proc Natl Acad Sci U S A 1995;92:6981-5.
36. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994;57:406-12.
37. Amorino GP, Deeble PD, Parsons SJ. Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway. Oncogene 2006;26:745-56.
38. Wright ME, Tsai MJ, Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol Endocrinol 2003;17: 1726-37.
39. Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999;39:135-48.
40. Jin RJ, Wang Y, Masumori N, et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res 2004;64:5489-95.
41. Roudier MP, True LD, Higano CS, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastasis to bone. Hum Pathol 2003;34:646-53.
42. Kvissel AK, Ramberg H, Eide T, Svindland A, Skalhegg BS, Tasken KA. Androgen dependent regulation of protein kinase A subunits in prostate cancer cells. Cell Signal 2006;19:401-9. Epub 2006 Jul 25.
43. Zelivianski S, Verni M, Moore C, Kondrikov D, Taylor R, Lin MF. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim Biophys Acta 2001;1539: 28-43.